SAN FRANCISCO, Feb. 8, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announces the nationwide launch of AmnioFix ® Injectable, the Company's newest tissue offering. MiMedx is formally unveiling AmnioFix ® Injectable today during the first day of the American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting being held in San Francisco, California. AmnioFix ® Injectable is an allograft composed of micronized amniotic tissue, uniquely processed to optimize surgical performance and ease of use. The Company's proprietary Purion ™ process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue. The result is an injectable tissue that offers surgeons a clear advantage due to its natural ability to reduce inflammation at the injection site and enhance soft tissue healing. Another significant advantage for physicians is the five-year, room temperature shelf life of AmnioFix ® Injectable. In addition to AmnioFix ® Injectable, MiMedx is also highlighting AmnioFix ® Wrap for both nerve and tendon applications. AmnioFix ® Wrap is another of the MiMedx tissue offerings from the Company's AmnioFix ® technology platform. AmnioFix ® Nerve Wrap, an allograft from amniotic tissue that is utilized for various nerve repair surgical procedures, was formally launched during 2011. The Company's newest AmnioFix ® Wrap allograft is designed for both nerve and tendon repair surgical procedures. AmnioFix ® Wrap is a composite allograft structure of amniotic membrane layers, uniquely processed through the Company's proprietary Purion ™ process to optimize surgical performance and ease of use. For use as an in-vivo wrap in peripheral nerve and tendon trauma, AmnioFix ® Wrap provides a protective barrier and contributes to the three phases of the natural healing process. . . inflammatory phase, proliferation phase and remodeling phase. In-vivo studies have confirmed that the properties of amniotic membrane help to reduce scar tissue formation and scar attachments to injured/repaired nerves and tendons. Parker H. "Pete" Petit, Chairman and CEO, said, "During the conference, we are exhibiting the Company's full suite of biomaterial platform technologies developed for use in soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine. We are expanding our presence at the AAOS in order to serve the growing interests among physicians for minimally manipulated tissue offerings that address the clinical efficacy and cost effectiveness needs of these critical areas of healthcare."